Vericel (NASDAQ:VCEL) is set to post its quarterly earnings results before the market opens on Tuesday, November 6th. Analysts expect Vericel to post earnings of ($0.10) per share for the quarter.
Vericel (NASDAQ:VCEL) last posted its earnings results on Monday, August 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). The business had revenue of $19.01 million for the quarter, compared to analyst estimates of $18.51 million. Vericel had a negative return on equity of 37.86% and a negative net margin of 23.35%. On average, analysts expect Vericel to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
VCEL stock opened at $12.02 on Monday. The company has a current ratio of 7.72, a quick ratio of 7.48 and a debt-to-equity ratio of 0.16. The company has a market cap of $513.57 million, a P/E ratio of -24.04 and a beta of 3.36. Vericel has a 1-year low of $3.30 and a 1-year high of $15.29.
A number of research analysts have commented on VCEL shares. Needham & Company LLC decreased their price objective on Vericel from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, August 8th. LADENBURG THALM/SH SH raised Vericel from a “neutral” rating to a “buy” rating in a report on Monday, July 16th. BTIG Research reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Vericel in a report on Tuesday, August 7th. Finally, BidaskClub lowered Vericel from a “hold” rating to a “sell” rating in a report on Tuesday, October 23rd. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $15.00.
In other Vericel news, CFO Gerard J. Michel sold 15,000 shares of the company’s stock in a transaction on Monday, September 10th. The stock was sold at an average price of $12.35, for a total value of $185,250.00. Following the transaction, the chief financial officer now directly owns 165,960 shares of the company’s stock, valued at approximately $2,049,606. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Dominick Colangelo sold 75,000 shares of the company’s stock in a transaction on Thursday, October 4th. The shares were sold at an average price of $15.02, for a total value of $1,126,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 114,000 shares of company stock worth $1,609,770. Insiders own 3.30% of the company’s stock.
A hedge fund recently raised its stake in Vericel stock. Bank of New York Mellon Corp raised its position in Vericel Corp (NASDAQ:VCEL) by 4.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 132,888 shares of the biotechnology company’s stock after buying an additional 5,854 shares during the quarter. Bank of New York Mellon Corp owned 0.31% of Vericel worth $1,289,000 at the end of the most recent reporting period. 76.53% of the stock is currently owned by institutional investors and hedge funds.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.
Further Reading: Does the discount rate affect the economy?
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.